Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
27 Feb 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
26 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
18 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Departure of Directors or Certain Officers
1 Dec 23
8-K
Regulation FD Disclosure
30 Nov 23
8-K
Regulation FD Disclosure
3 Nov 23
8-K
Regulation FD Disclosure
3 Nov 23
8-K
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
2 Nov 23
8-K
BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013
26 Oct 23
8-K
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
3 Aug 23
Registration and prospectus
S-3ASR
Automatic shelf registration
27 Feb 24
S-8
Registration of securities for employees
8 Nov 23
S-8
Registration of securities for employees
30 Jun 23
S-8
Registration of securities for employees
31 Aug 22
S-8
Registration of securities for employees
14 Jul 22
S-8
Registration of securities for employees
30 Sep 21
424B5
Prospectus supplement for primary offering
9 Aug 21
S-8
Registration of securities for employees
28 May 21
S-8
Registration of securities for employees
28 May 21
S-3ASR
Automatic shelf registration
1 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
26 May 22
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
DEFA14A
Additional proxy soliciting materials
13 Apr 21
DEF 14A
Definitive proxy
13 Apr 21
DEFA14A
Additional proxy soliciting materials
31 Mar 20
Other
UPLOAD
Letter from SEC
18 Jan 22
CORRESP
Correspondence with SEC
14 Jan 22
UPLOAD
Letter from SEC
14 Dec 21
SEC STAFF
SEC staff action: Order
22 Mar 21
EFFECT
Notice of effectiveness
15 May 20
CORRESP
Correspondence with SEC
12 May 20
CORRESP
Correspondence with SEC
4 May 20
CT ORDER
Confidential treatment order
1 May 20
UPLOAD
Letter from SEC
27 Apr 20
CT ORDER
Confidential treatment order
17 Dec 18
Ownership
4
Helen M. Thackray
2 Apr 24
4
VINCENT MILANO
4 Mar 24
4
THERESA HEGGIE
4 Mar 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13G/A
STATE STREET CORP
24 Jan 24
4
Jon P Stonehouse
4 Jan 24
4
Helen M. Thackray
20 Dec 23